Immunotherapy for Parkinson's disease: stay tuned

All patients were in early stages of disease, and not all were on levodopa at study entry. Because the study was exploratory, no correction was made for multiple comparisons. [...]α-synuclein plays a part in regulation of neurotransmitter release and in synaptic plasticity and learning, and it will therefore be important to do long-term monitoring of patients to see if there are unanticipated deleterious effects related to the loss of the physiological function of α-synuclein. Science Photo Library AJS receives honoraria as chair of the data safety monitoring board for a trial (Voyager, Neurocrine Biosciences) of AADC gene therapy for Parkinson's disease and has received a speaker honorarium from AbbVie.